Pemtumomab

Pemtumomab is a monoclonal antibody that was developed for the treatment of cancer. It is a type of immunotherapy, which uses the body's immune system to fight cancer. Pemtumomab was designed to target and bind to a specific protein found on the surface of cancer cells, thereby marking them for destruction by the immune system.

History

Pemtumomab was originally developed by Cancer Research UK, a leading cancer research and awareness charity in the United Kingdom. It was later licensed to Xenova Group, a biopharmaceutical company, for further development and commercialization. However, the development of Pemtumomab was discontinued in the early 2000s due to lack of efficacy in clinical trials.

Mechanism of Action

Pemtumomab is a radiolabeled antibody, meaning it is attached to a radioactive substance. It works by binding to a specific protein called tumor-associated glycoprotein 72 (TAG-72), which is overexpressed in many types of cancer, including ovarian cancer and colorectal cancer. Once Pemtumomab binds to TAG-72, the radioactive substance can deliver a lethal dose of radiation directly to the cancer cell, sparing healthy cells.

Clinical Trials

Several clinical trials were conducted to evaluate the safety and efficacy of Pemtumomab in the treatment of various types of cancer. However, the results were not promising. In a phase III clinical trial involving patients with ovarian cancer, Pemtumomab did not show a significant improvement in overall survival compared to standard treatment. As a result, the development of Pemtumomab was discontinued.

See Also

• Monoclonal antibodies in oncology
• Cancer immunotherapy
• Radiolabeled antibody